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Abstract
Background
Rifampicin-resistant tuberculosis (RR-TB) is largely underdetected in Indonesia. Xpert
MTB/RIF (Xpert) has recently been introduced, prioritizing patients at risk of RR-TB, fol-
lowed by phenotypic drug-susceptibility (DST) if rifampicin resistance is detected.
Objective
This study investigated Xpert-based management of presumptive RR-TB cases under rou-
tine practice in West Java, Indonesia.
Methods
We examined all records of patients tested with Xpert in the referral hospital for West Java
in 2015–2016. We measured loss across a limited cascade of care, time to Xpert diagnosis
and the commencement of initial second-line treatment, and identified factors associated
with diagnostic and treatment delay. Additionally, we analyzed the appropriateness of treat-
ment according to DST results.
Results
Of 3415 patients with presumptive RR-TB, 3215 (94%) were tested by Xpert, of whom 339
(10.5%) were diagnosed as RR-TB. 288 (85%) of 339 RR-TB patients started initial second-
line TB treatment, with 48 (14%) patients being lost between diagnosis and pre-treatment
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assessment. Second-line treatment was commenced at a median of 41 days (IQR 29–70)
after RR-TB diagnosis. Delays in both diagnosis and treatment initiation were observed in
104 (52%) of 201 RR-TB patients with identifiable referral date. Rural residence was associ-
ated with delay to diagnosis (adjusted OR 2.7; 95%CI 1.5–5.2) and treatment initiation
(adjusted OR 2.0; 1.2–3.4). Of 162 patients with available DST result, 107 (66%) had multi-
drug-resistant tuberculosis (MDR-TB) and 32 (20%) had either pre-extensively drug resis-
tant (pre-XDR) or extensively drug resistant tuberculosis (XDR-TB). We estimated that with
the current algorithm 41% of pre-XDR or XDR-TB patients are diagnosed, and 33% of them
started on an appropriate treatment regimen.
Conclusions
Many patients with Xpert-diagnosed RR-TB either do not start MDR-TB treatment or
encountered diagnostic and treatment delays under programmatic conditions in Indonesia,
and most pre-XDR and XDR-TB cases remain undiagnosed. Further expansion and ongo-
ing quality improvement of RR-TB services are urgently needed.
Introduction
The emergence of rifampicin-resistant tuberculosis (RR-TB) has become a threat to global TB
control. Suboptimal TB treatment, poor treatment outcomes, low adherence to TB treatment, and
poorly regulated private sectors have contributed to the increase of MDR-TB [1, 2]. Most incident
of RR-TB cases are thought to result from direct transmission rather than treatment-related resis-
tance acquisition [3], like in South Africa where 52% of RR-TB is caused by direct transmission
[4]. Thus, improving RR-TB diagnosis should be a high priority. Xpert MTB/RIF assay (Xpert)
allows for universal limited drug-susceptibility testing (DST) with rapid detection of RR-TB [5].
The World Health Organization (WHO) recommends Xpert as an initial diagnostic tool for pre-
sumptive RR-TB patients [6]. Since 2011, the global roll-out of Xpert has increased detection of
RR-TB diagnosis three- to eight-fold compared to conventional testing [7].
Indonesia has the second highest number of TB cases globally, with an estimated TB preva-
lence of 647/100,000, and it is also considered a high burden RR-TB country [8]. The latest
drug-resistance survey in Indonesia reported RR-TB in 2% of new cases and 9.7% of re-treat-
ment cases [9]. The Indonesian National TB Programme (NTP) has adopted Xpert as a front-
line test to detect RR-TB since 2012, yet only a limited number of healthcare facilities have
access to Xpert and many patients have restricted access to second-line TB treatment [10]. As
a result, RR-TB very often remains undetected and untreated, leading to further spread of
drug resistance, worse TB treatment outcomes and increased mortality [11].
History of multiple previous TB treatment, younger age, and irregular treatment, HIV
infection [12], and diabetes [13] have been reported risk factors for RR-TB acquisition [1, 14–
16], whereas previous TB treatment, resistance to ofloxacin, being smear-positive at the start
of treatment, and no culture conversion by the 3rd month of treatment have been associated
with poor MDR-TB treatment outcomes [17–19]. Various studies have reported diagnosis and
treatment outcomes of RR-TB using Xpert as rapid DST [20–24]. Several studies have analysed
the cascade of care for RR-TB under programmatic conditions [25–29], however, none have
been performed in Indonesia. A cascade of care study from India’s public sector showed that a
substantial proportion of MDR-TB patients who reached the NTP diagnostic facilities were
not successfully diagnosed [25]. Therefore, we aimed to evaluate Xpert-based management of
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presumptive RR-TB cases under routine programmatic conditions in West Java, Indonesia,
focusing on loss across a limited cascade of care from patient’s registration at Xpert facility to
treatment initiation, diagnostic and treatment delay, and the identification of associated risk
factors.
Materials and methods
Study setting
We performed a retrospective cohort study of adults with presumptive RR-TB who were regis-
tered for Xpert testing between 1 January 2015 and 31 December 2016 at the ‘programmatic man-
agement of drug-resistant tuberculosis (PMDT)’ clinic of Dr. Hasan Sadikin Hospital, the main
referral site for patients with RR-, MDR-, pre-XDR- and XDR-TB in West Java (population: 46.4
million). In West Java, at the time of data collection, there were four hospitals with Xpert and only
two that provided PMDT service, as authorized by the Ministry of Health. We excluded patients
with a previous history of RR-TB treatment because their referral pattern is different from the pre-
sumptive RR-TB cases in our health system as they can directly seek care to PMDT clinic.
A presumptive RR-TB case was defined as an individual who has one or more risk factors
for RR-TB according to Indonesian PMDT guidelines [9] (S1 Table) and registered at the
PMDT clinic. With respect to an initial treatment regimen, MDR-TB is defined pragmatically
as TB with rifampicin-resistance based on Xpert result. Patient with RR-TB detected by Xpert
are treated empirically with a standard MDR-TB regimen while awaiting complete phenotypic
DST results. Standard MDR-TB treatment in Indonesia consists of Kanamycin (Km) injec-
tions for a minimum eight months as initial phase and ethionamide (Eto) or prothionamide,
levofloxacin (Lfx) or moxifloxacin, cycloserine (Cs) or p-aminosalicylic acid, pyrazinamide (Z)
and ethambutol (E) (if no resistance was detected) for at least 20 months. When DST results
indicate additional resistance, either pre-XDR or XDR-TB, the clinical expert team adjusts the
treatment regimen accordingly, following the national PMDT guidelines [9]. Sputum culture
and DST for Dr. Hasan Sadikin Hospital are routinely performed at the provincial reference
laboratory in Bandung. Culture was done using solid or liquid media (MGIT). DST assesses
resistance to first-line drugs (rifampicin, isoniazid, ethambutol, and streptomycin), and a lim-
ited number of second-line drugs (kanamycin, amikacin, ofloxacin).
Outcome measures
We used the conceptual framework described in Fig 1. We measured time between initial
smear microscopy and the Xpert result as time to RR-TB diagnosis, and defined diagnostic
delay as more than 14 days, on the basis of the median recorded time in our data. We defined
initial treatment delay as more than 15 days between the Xpert result confirming RR-TB and
the start date of MDR-TB treatment, in line with a previous study [30].
Data collection and analysis
Presumptive RR-TB patients were identified from the clients’ register. We extracted data from
the routine clinic staff assessment of patients, using a structured data collection tool gathering
information about TB symptoms, sociodemographic characteristics, referral origin, risk factors
for RR-TB, drug-sensitive TB (DS-TB) treatment history, and history of seeking care from pri-
vate practitioners. We accessed laboratory results electronically through data linkage by
matching patients’ unique identification numbers. The times between smear microscopic TB
diagnosis (mostly at other TB clinics), phenotypic DST results, and between Xpert testing and
second-line treatment were extracted from medical records and the electronic register.
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Appropriateness of second-line treatment was determined by the clinical expert team by
assessing the DST results, patient TB treatment history and clinical symptoms [31].
We classified the type of residence according to whether the patients lived in or outside
Bandung. The dates of smear microscopy results were obtained from referral letters from
lower level healthcare providers. The date of the Xpert result was taken from the laboratory
register at the hospital. We obtained the date of pre-treatment assessment and second line
treatment initiation from the medical records.
Data were analyzed using IBM SPSS Statistics version 20. We used a simple extrapolation to
estimate overall Xpert positivity and overall proportions of MDR-, pre-XDR- and XDR-TB for
a cascade of care analysis. We plotted Kaplan Meier survival curves to illustrate both times to
cascade step completion and proportion completing the step. Those lost-to-follow up were
right censored at 180 days for each step. We conducted multivariable logistic regression to ana-
lyze risk factors associated with diagnosis and treatment delay using backward-stepwise
method. The multivariable models included gender, age, type of residence, income, presump-
tive MDR-TB criteria, and frequency of previous DS-TB treatment as covariates. In the multi-
variable analyses, a p-value < 0.05 was considered statistically significant, and the adjusted
odds ratio (AOR) and 95% confidence intervals (CI) were reported. Ethical clearance for this
study was provided by the Health Research Ethics Committee at Faculty of Medicine, Univer-
sitas Padjadjaran under number 712/UN6.C2.1.2/KEPK/PN/2014. Informed consent was
waived by the Ethics Committee as this was a retrospective analysis of secondary data. Further,
the data from patient records were de-identified and analyzed anonymously.
Results
Xpert testing and MDR-TB treatment
From the clinic register, there were 3415 presumptive cases of RR-TB, of whom 3215 (94.1%)
were tested with Xpert. The presumptive RR-TB cases had a median (IQR) age of 40 (31–52)
Fig 1. Time to diagnosis and treatment of presumptive rifampicin-resistant TB using Xpert. Time between microscopic
TB diagnosis and patient presentation for Xpert examination (a), Xpert result (b), time between Xpert result and patients visit
for pre-treatment assessment (c), initiation of second line treatment (d), total time between microscopic TB diagnosis and
diagnosis of RR-TB (e), and total time between RR-TB diagnosis and start of second line treatment (f). Total time between
microscopic TB diagnosis and start of MDR-TB treatment (g).
https://doi.org/10.1371/journal.pone.0213017.g001
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years, 54.5% were male and 53.0% were referral cases from outside Bandung. Of those tested,
118 had a failed test and 339 (10.5%, Fig 2) patients were identified with RR-TB. Those diag-
nosed with RR-TB had a mean age of 38 years, 56.9% were male, over 2/3 were from outside
Bandung and 21.5% were urban migrants, who had left their rural hometowns where they
were registered (Table 1). Most (55.5%) had been referred because of failure of drug-sensitive
TB treatment, almost all (97.1%) had DS-TB treatment history. Two hundred and eighty-eight
(84.9%) started MDR-TB treatment at some point. Within the clinic system the step with the
biggest loss to follow-up in the care cascade was between Xpert result and pre-treatment exam-
ination (48 of 339 [14.2%]; Fig 3).
Time to diagnosis and treatment of rifampicin-resistant TB
The median time to diagnosis of RR-TB for those who did attend the clinic was 14 days (IQR
7–29; Fig 3), noting that there were no data available on those who were referred but did not
attend the PMDT clinic. It took a median of 10 days (IQR 5–24) from having the smear
microscopy result at a primary or secondary healthcare provider (HCP) and a patient’s visit to
the PMDT clinic. The median duration between submitting sputum and getting the Xpert
result was two days (IQR 1–4; Fig 4A). Gender, age, income, presumptive RR-TB criteria, and
frequency of previous TB treatment were not associated with diagnostic delay (Table 2). How-
ever, patients who came from outside Bandung were more likely to have a diagnostic delay
(odds ratio 2.7; 95% CI: 1.5–5.2).
The median time to start second-line treatment was 25 days (IQR 15–67). After having an
Xpert result, it took a median of 18 days (IQR 8–47) for patients to visit the PMDT clinic for
pre-treatment examination (Fig 4B), and a median of 6 days between pre-treatment assess-
ment and start of second-line treatment (IQR 0–8; Fig 4C). Patients who came from outside
Bandung were more likely to have treatment delay (odds ratio 2.0; 95%CI: 1.2–3.4; Table 2).
Overall, the median time between TB diagnosis and start of second-line treatment was 41 days
(IQR 29–70), and 104 (51.7%) of 201 RR-TB patients with identifiable referral date experi-
enced both diagnostic and treatment delays.
Phenotypic drug susceptibility testing results and treatment adjustment
Sputum culture results were available for 243 patients (71.7%) and phenotypic DST results for
162 (47.8%) of 339 patients with Xpert-positive RR-TB. Phenotypic DST identified 107 of 339
patients with Xpert RR-TB as having MDR-TB (31.6%), 28 patients (8.3%) as having pre-
XDR-TB- mostly with fluoroquinolone resistance, 4 (1.2%) as having XDR-TB (Table 3), and
23 (6.8%) as not having MDR-TB. No phenotypic DST was available for 177 patients (52.1%)
who had a negative culture, a non-tuberculous mycobacteria (NTM) as culture result, a con-
taminated culture, or no culture result. Focusing on those with a DST result who started
MDR-TB treatment (n = 158), we confirmed 6 (3.8%) as RIF mono-resistance, 105 (66.5%) as
MDR-TB, 30 (18.9%) as preXDR- or XDR-TB (Fig 2). 129 (79.6%) of 135 patients with con-
firmed MDR-, pre-XDR- or XDR-TB phenotypically received an appropriate treatment regi-
men at some point (Fig 2). For 17 RR-TB patients with phenotypically confirmed RIF-
susceptibility, MDR-TB treatment was continued without further adjustment.
Estimation of the number of pre-XDR and XDR-TB patients
We estimated the number of patients with pre-XDR- and XDR-TB who were likely to have
been missed by the system. Assuming that proportion with Xpert RIF resistance among 3415
MDR-TB suspects entering the system was the same among those who were tested as those not
tested or had a failed test, overall 374 referred patients were estimated to have had Xpert RIF
Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant TB in Indonesia
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resistance. Based on simple extrapolation from the phenotypic DST results in those with a test
result, it can be estimated that 65 of these patients had pre-XDR TB and 9 had XDR-TB.
Fig 2. Flow chart of study participants. MDR-TB: Multidrug-resistant TB, PMDT: Programmatic Management of Drug-resistant TB, NTM: Non-tuberculous
Mycobacteria, DST: phenotypic Drug Susceptibility Testing. �pre-XDR (n = 27) and XDR (n = 3). �� Appropriate treatment was defined as compatibility
between DST result and the choice of drug-resistant treatment regimen. ���Patients with DST result not suggesting MDR continued their 2nd line treatment
according to Indonesian PMDT guideline. aThe 200 patients were not tested due to possible reasons, which were: 1) patients didn’t present to the laboratory for
Xpert testing; 2) patients weren’t able to expectorate sputum.
https://doi.org/10.1371/journal.pone.0213017.g002
Table 1. Characteristics of Xpert rifampicin-resistant TB patients (n = 339).
Characteristics n (%)�
Male 193 (56.9)
Age (mean ± SD) 38.2 ± 12.5
HIV positive�� 5 (1.5)
Residence
Outside Bandung 231 (68.1)
Bandung 108 (31.9)
Employment status
Unemployed 83 (24.5)
Retired, housewife, student 124 (36.6)
Employed 132 (38.9)
Monthly household income
Do not have income 175 (51.6)
< 74 USD± 35 (10.3)
74–148 USD 80 (23.6)
>148 USD 49 (14.5)
Presumptive MDR-TB criteria
Failure on HRZE/HRZES 188 (55.5)
Treatment default 29 (8.6)
Relapse 113 (33.3)
Contact with MDR-patient 4 (1.2)
History/current use of insufficient treatment regimen 5 (1.5)
History of drug-sensitive TB treatment
None 7 (2.1)
Once 124 (36.6)
Twice 132 (38.9)
> 2 times 76 (22.4)
Sought care from private practitioners
Yes 45 (13.3)
No 294 (86.7)
Source of referral for Xpert test
Distric public hospital 139 (41.0)
Private hospital 34 (10.0)
Private practitioners 11 (3.3)
Primary Health Centre 131 (38.6)
Lung Clinic 24 (7.1)
�unless otherwise stated.
��Data were missing for HIV status (8.6%).
±1USD = 13,300 Indonesian Rupiah (IDR).
https://doi.org/10.1371/journal.pone.0213017.t001
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Therefore, we estimated that almost a fifth, 74 out of 374 patients with RIF resistance entering
the system would have had pre-XDR-TB or XDR-TB, but that only 30 (40.6%) were identified
and 24 (32.5%) were commenced on an appropriate regimen.
Discussion
This study has identified specific losses and delays with respect to diagnosis and treatment ini-
tiation of RR-TB in Indonesia. Of 3415 patients referred with presumptive RR-TB over a
2-year period, almost 10% (n = 339) were diagnosed with Xpert RR-TB. For this group it took
a median of two weeks to obtain an Xpert result and an additional 25 days until start of sec-
ond-line treatment, with 14% of patients lost between diagnosis and MDR-TB treatment initi-
ation. Patients who came from outside the city were more likely to have diagnostic and
treatment delay. Just over half of those with Xpert-diagnosed RR-TB who started initial sec-
ond-line treatment had a phenotypic DST result. Of those with DST results, 66% had
MDR-TB and 20% had either pre-XDR or XDR-TB. If the phenotypic DST data are extrapo-
lated to the whole study population of registered patients, then the system diagnosed only 41%
of pre-XDR or XDR-TB patients and started only 33% on an appropriate treatment regimen.
Together these data provide important insights into the challenges of diagnosing and treating
DR-TB in this setting.
Fig 3. Cascade of care and time to diagnosis and treatment of Xpert rifampicin-resistant TB patients. Values in the bars indicate number
(percentages). �12 of 118 with a failed result were imputed as Xpert positive and assigned the censored time of 180 days. ��Pre-treatment examination
included blood & urine test, HIV test, chest X-ray, audiometry and psychiatric assessment. ���Data were only available for 201 patients. Median (IQR)
times between: microscopic TB diagnosis and patient presentation for Xpert examination (a), Xpert examination and Xpert result (b), Xpert result and
visit for pre-treatment assessment (c), pre-treatment assessment and initiation of second line treatment (d), microscopic TB diagnosis and diagnosis of
RR-TB (e), Xpert result and initiation of second line treatment (f), microscopic TB diagnosis and initiation of second-line treatment (g).
https://doi.org/10.1371/journal.pone.0213017.g003
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Currently, in West Java province, healthcare facilities equipped with Xpert are centralized
in urban areas, which likely explains the poorer performance of the system for patients from
outside the city. Our hospital is the tertiary level hospital in West Java, providing referral ser-
vices for patients from lower-level healthcare providers in 18 regencies and 9 municipalities
that serve a total population of 46.4 million. Among RR-TB patients from outside the city, one
third were urban migrants. Previous studies in China have shown that urban migrants have
higher TB rates, more drug resistance, and poorer treatment outcomes than urban residents
[32, 33]. Several decentralized models of care for MDR-TB have been introduced to improve
the linkage between diagnosis and treatment initiation especially for patients from rural areas
[34, 35]. MDR-TB patients treated under community-based care involving healthcare workers
and treatment supporters at sub-district or village level achieved equally high treatment suc-
cess as those with hospital-based initiation [36].
Referral of patients to PMDT hospital for Xpert testing took a median of 10 days, in line
with a study in India which showed a median delay of 8 days [37]. In a study in South Africa,
diagnostic delay was caused by patient delays, failure to make a diagnosis at the first visit, and
patients visiting public and private health care settings at the same time [38]. Negative percep-
tions of the public sector (over-burdened, long waiting times, negative attitudes of health care
Fig 4. Kaplan Meier curves for time between specific cascade of care steps. These figures show Kaplan-Meier time-
to-event graphs for specific cascade of care steps between registration and Xpert result (n = 351) (A), Xpert result and
pre-treatment examination (n = 339) (B), and pre-treatment examination and MDR-TB treatment initiation (n = 291)
(C).
https://doi.org/10.1371/journal.pone.0213017.g004
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staff, lack of privacy), lack of money for transport, and lack of awareness that TB can relapse
have been identified as barriers to prompt diagnosis [39]. In addition, major financial and
social support constrains are underlying barriers [40].
The pre-treatment loss (one in seven) was surprisingly high in this study, despite the use of
Xpert testing. Clinic staff reported that they called these patients multiple times, but that no
home visits were done. Other studies have identified health system issues as important with
respect to drop out, including: poor recording of patient contact details [41]; poor follow-up
due to overwhelmed healthcare workers; interruptions due to dissatisfaction with the service;
work and family commitments; and test results not being ready at follow-up appointments
[39, 42]. In our study, we had to retrieve Xpert RIF resistant results from the laboratory register
and second-line treatment data from the clinic database. As has been reported for other set-
tings, insufficient linkage of such data systems increases the risk that patients with DR-TB are
not started on treatment or are started on inappropriate regimens [43].
There was a considerable delay (median of 25 days) between Xpert diagnosis of RIF resis-
tance and start of second-line treatment, even longer than reported in a previous study in
Indonesia (median 15 days) [30], but similar to studies from other settings [20, 43, 44]. A sys-
tematic review reported that time from DR-TB diagnosis to second line treatment was shorter
with genotypic than with phenotypic DST (38 versus 108 days) [45]. Rapid treatment initiation
following RR-TB diagnosis is essential for TB control as it optimizes treatment outcomes, min-
imises disease transmission, and reduces further drug resistance [46, 47]. Optimal linkage to
second line treatment will be similarly important.
Our data are in line with other studies showing that implementation of Xpert increases
detection of RR-TB but that the clinical impact of this rapid DST is modest in weak health sys-
tems marked by gaps between diagnosis and treatment initiation [43, 48–50]. The roll-out of
Xpert as universal DST has been hampered by high costs of scale-up, infrastructural problems
Table 2. Multivariable analysis of factors associated with diagnostic and treatment delay of rifampicin-resistant TB patients.
Variable Diagnostic delay (n = 201) Treatment delay (n = 339)
n (%) OR 95% CI AOR 95% CI n (%) OR 95% CI AOR 95% CI
Male 57 (49.6%) 1.2 0.7–2.2 1.1 0.6–1.9 138 (71.5%) 0.8 0.5–1.4 0.8 0.5–1.3
Age (years) 38.5±13.5 1.0 0.9–1.0 1.0 0.9–1.0 38.6±12.5 1.0 0.9–1.0 1.0 0.9–1.0
Residence:
Bandung 19 (30.6%) Reference Reference 70 (64.8%) Reference Reference
Outside Bandung 76 (54.7%) 2.7 1.4–5.1�� 2.7 1.5–5.2�� 177 (76.6%) 1.8 1.1–2.9 2.0 1.2–3.4��
Monthly household income:
Do not have income 44 (46.8%) Reference Reference Reference Reference
< 74 USD 15 (48.4%) 1.1 0.5–2.4 0.9 0.4–2.1 24 (68.6%) 0.8 0.4–1.8 0.8 0.3–1.8
74–148 USD 21 (44.7%) 0.9 0.5–1.9 0.8 0.4–1.8 54 (67.5%) 0.8 0.4–1.4 0.7 0.4–1.3
>148 USD 15 (51.7%) 1.2 0.5–2.8 1.3 0.5–3.1 42 (85.7%) 2.3 0.9–5.4 2.5 1.0–6.0
Presumptive MDR-TB criteria:
Treatment failure 65 (48.5%) 1.2 0.6–2.1 1.2 0.7–2.2 138 (75%) 1.3 0.8–2.0 1.3 0.8–2.1
Other criteria� 30 (44.8%) Reference Reference 109 (70.3%) Reference Reference
Frequency of previous TB treatment:
� 2 times 68 (44.7%) Reference Reference 188 (71.5%) Reference Reference
> 2 times 27 (55.1%) 1.5 0.8–2.9 1.3 0.7–2.6 59 (77.6%) 1.4 0.8–2.5 1.3 0.7–2.5
OR: odds ratio; AOR: adjusted odds ratio.
�Other criteria: default, relapse, contact history with MDR-TB patients, TB-HIV co-infection and history/current use of insufficient treatment regimen.
��p<0.05.
https://doi.org/10.1371/journal.pone.0213017.t002
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such as lack of uninterrupted power supply, maintenance and technical support, interruptions
in the supply chain, and lack of monitoring and supervision [7, 21].
It is of concern that less than half of patients with Xpert RR-TB had a phenotypic DST result
to guide treatment, especially for those patients with pre-XDR or XDR-TB. Failure to detect
additional drug resistance results in inadequate treatment regimens that contribute to poor
treatment outcomes and higher mortality [51]. Culture is not routinely performed in Indone-
sia; only a fraction of patients put on TB treatment have their sputum cultured. Failed culture
may be due to inability to collect sputum or sputum of good quality [52, 53], sample processing
[54], contamination, or other laboratory issues. In our study, we found that 17 of RR-TB
patients had RIF susceptibility on phenotypic DST, indicating the need for repeat DST testing
and/or post-hoc rpoB gene sequencing to reconcile the discordant results [55].
Currently, sputum smear microscopy is the frontline diagnostic tool in primary healthcare
settings in many high burden TB countries [56]. Xpert as a more sensitive diagnostic tool for
TB remains underutilised in many countries, including Indonesia [57]. Widespread uptake of
Table 3. Sputum culture and phenotypic drug resistance of 243 Xpert rifampicin-resistant TB patients.
Test n (%)
Sputum culture (n = 243)
Positive 162 (66.7)
Negative 57 (23.5)
Non-tuberculous mycobacteria 16 (6.6)
Contaminated 8 (3.3)
Individual drug-resistance (n = 162)
Rifampicin 145(89.5)
Isoniazid 128 (79.0)
Ethambutol 95 (58.6)
Streptomycin 67 (41.4)
Kanamycin# 8 (4.9)
Amikacin# 4 (2.5)
Ofloxacin# 33 (20.4)
Drug resistance by definition (n = 162)
MDR-TB� 107 (66.0)
Pre-XDR TB�� 28 (17.3)
Pre-XDR with injectables resistance 2 (1.2)
Pre-XDR with fluoroquinolone resistance 26 (16.1)
XDR-TB��� 4 (2.5)
RIF monoresistance 6 (3.7)
INH monoresistance 3 (1.9)
Monoresistancea 1 (0.6)
Polyresistanceb 1 (0.6)
RIF-sensitive 12 (7.4)
#Missing data for two patients.
�Multidrug-resistant TB (MDR-TB): resistant to at least isoniazid and rifampicin.
��Pre-XDR TB: resistant to isoniazid and rifampicin and either a fluoroquinolone and second-line anti-TB injectable
drugs, but not both.
���Extensively drug-resistant TB (XDR-TB): resistant to isoniazid and rifampicin (as well as any fluoroquinolone and
at least one of three second-line anti-TB injectable drugs (amikacin, kanamycin and capreomycin.
aMonoresistance: resistance to one first-line anti-TB drug only.
bPolyresistance: resistance to more than one first-line anti-TB drug, other than both isoniazid and rifampicin.[8]
https://doi.org/10.1371/journal.pone.0213017.t003
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Xpert into primary or secondary level healthcare facilities as done in South Africa [58] will
facilitate RR-TB detection, but phenotypic DST remains important for all patients with posi-
tive results. As shown elsewhere [59–61], Xpert testing and phenotypic DST show some dis-
cordance underlining the need for systematic algorithms to bring resolution. Furthermore,
several diagnostic tools are in the pipeline to provide better detection of drug resistant TB such
as the GeneXpert OMNI, the Xpert Ultra and the Xpert XDR [62, 63].
Some patients may receive treatment outside the NTP, especially from private providers,
but they are unlikely to receive an appropriate treatment regimen [64]. Therefore, engagement
of private practitioners by the NTP in Indonesia is a high priority area. A study from India
showed that only an estimated 14% RR-TB cases were appropriately diagnosed and completed
MDR-TB therapy in the public sector, with many patients evaluated at diagnostic facilities but
few adequately diagnosed as MDR-TB [25]. Previous studies have also revealed critical gaps
along drug-resistant TB cascade of care [49, 65]. In a South African study, an estimated 88% of
RR-TB cases who accessed the diagnostic service received a diagnosis and 56% underwent sec-
ond-line treatment [26].
Our study has several limitations. First, our findings may not be fully representative of Indo-
nesia as data collection was only done in one tertiary hospital. Second, no data were available to
accurately estimate the population prevalence of RR-TB to enable estimation of the proportion
of RR-TB cases in the community entering the system. Third, this study did not take into
account the proportion of presumptive RR-TB cases who were failed to reach the Xpert facility,
which is one of the weakest links identified elsewhere across the TB cascade of care [66]. Fourth,
we did not gather more explanatory data with respect to possible patient-related delays, such as
for those who were registered at the PMDT clinic but failed to have an Xpert test, missed fol-
low-up appointments, seeking care at other healthcare facilities, and socio-economic obstacles.
Fifth, as noted above, we did not resolve discordant results between Xpert and phenotypic DST.
Sixth, we did not evaluate MDR-TB treatment outcomes, which is key for a complete cascade of
care analysis but beyond the scope of this study. Finally, since our study relied heavily on rou-
tine data, some information on baseline characteristics were missing.
To our best knowledge, this is the first study to report on losses and delays in diagnosis and
treatment in RR-TB patients under programmatic conditions in Indonesia. Many patients
with RR-TB were either lost to the system, experienced diagnostic or treatment delay, did not
have DST results, or were not commenced on an appropriate treatment regimen. Decentraliza-
tion of Xpert testing to district hospitals or primary healthcare facilities and private providers
will be an important step to scale-up Xpert, and more will have to be done to enhance quality
of culture-based DST and RR-TB management in Indonesia.
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